A Pathway to Personalizing Therapy for Metastases Using Liver-on-a-Chip Platforms
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Metastasis accounts for most cancer-related deaths. The majority of solid cancers, including those of the breast, colorectum, prostate and skin, metastasize at significant levels to the liver due to its hemodynamic as well as tumor permissive microenvironmental properties. As this occurs prior to detection and treatment of the primary tumor, we need to target liver metastases to improve patients’ outcomes. Animal models, while proven to be useful in mechanistic studies, do not represent the heterogeneity of human population especially in drug metabolism lack proper human cell-cell interactions, and this gap between animals and humans results in costly and inefficient drug discovery. This underscores the need to accurately model the human liver for disease studies and drug development. Further, the occurrence of liver metastases is influenced by the primary tumor type, sex and race; thus, modeling these specific settings will facilitate the development of personalized/targeted medicine for each specific group. We have adapted such all-human 3D ex vivo hepatic microphysiological system (MPS) (a.k.a. liver-on-a-chip) to investigate human micrometastases. This review focuses on the sources of liver resident cells, especially the iPS cell-derived hepatocytes, and examines some of the advantages and disadvantages of these sources. In addition, this review also examines other potential challenges and limitations in modeling human liver.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Innovation in the pharmaceutical industry: New estimates of R&D costs
DiMasi, J. A., Grabowski, H. G., & Hansen, R. W. (2016) · Journal of Health Economics · doi:10.1016/j.jhealeco.2016.01.012 · Cited by 3,359
Vascularized and functional human liver from an iPSC-derived organ bud transplant
Takebe, T., Sekine, K., Enomura, M., Koike, H., Kimura, M., Ogaeri, T., Zhang, R.-R., Ueno, Y., Zheng, Y.-W., Koike, N., et al. (2013) · Nature · doi:10.1038/nature12271 · Cited by 2,170 · cited 2×
“Tremendous breakthroughs using iPS cells have been reported including successful liver bud development and implantation to treat liver failure in mice [89] and whole mice generation from iPS cells [90].”
BackgroundGender Disparity in Liver Cancer Due to Sex Differences in MyD88-Dependent IL-6 Production
Naugler, W. E., Sakurai, T., Kim, S., Maeda, S., Kim, K., Elsharkawy, A. M., & Karin, M. (2007) · Science · doi:10.1126/science.1140485 · Cited by 1,955
Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients
Bubendorf, L., Schöpfer, A., Wagner, U., Sauter, G., Moch, H., Willi, N., Gasser, T. C., & Mihatsch, M. J. (2000) · Human Pathology · doi:10.1053/hp.2000.6698 · Cited by 1,895 · cited 1×
“About 8% of prostate cancer patients develop clinically evident liver metastases during their treatment period [26] and a much higher percentage (25–45%) of prostate cancer patients show liver involvement at autopsy [15, 27].”
BackgroundHighly efficient generation of human hepatocyte-like cells from induced pluripotent stem cells
Si-Tayeb, K., Noto, F. K., Nagaoka, M., Li, J., Battle, M. A., Duris, C., North, P. E., Dalton, S., & Duncan, S. A. (2010) · Hepatology · doi:10.1002/hep.23354 · Cited by 1,282 · cited 1×
“Some protocols demonstrated impressive hepatocyte induction but may require prolongedmaturation period to completely abolish AFP expression [101, 103, 115].”
BackgroundWilkening, S., Stahl, F., & Bader, A. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.8.1035 · Cited by 794
Gillet, J.-P., Calcagno, A. M., Varma, S., Marino, M., Green, L. J., Vora, M. I., Patel, C., Orina, J. N., Eliseeva, T. A., Singal, V., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1111840108 · Cited by 477 · cited 1×
“In addition, cell line models for ovarian cancer, glioblastoma, colorectal cancer and metastatic melanoma failed to mimic the gene expression pattern of multi-drug receptor of primary cultures [153].”
BackgroundGeneration of Functional Human Hepatic Endoderm From Human Induced Pluripotent Stem Cells
Sullivan, G. J., Hay, D. C., Park, I.-H., Fletcher, J., Hannoun, Z., Payne, C. M., Dalgetty, D., Black, J. R., Ross, J. A., Samuel, K., et al. (2010) · Hepatology · doi:10.1002/hep.23335 · Cited by 445 · cited 4×
“Sullivan et al. induced iPS cells from three different genetic backgrounds into ALB+ and E-cadherin+ hepatic endoderm and were able to detect the secretion of AFP, fibronectin and fibrinogen in all cell lines that also displayed functional CYP1A2 and CYP3A4 activity but with significant variability in iPS cells derive…”
MethodResultInfluentialUse of rodents as models of human diseases
Vandamme, T. (2014) · Journal of Pharmacy And Bioallied Sciences · doi:10.4103/0975-7406.124301 · Cited by 389
Lee, H., & Cho, D.-W. (2016) · Lab on a Chip · doi:10.1039/c6lc00450d · Cited by 363 · cited 4×
“Some studies utilize common cell lines such as HUVEC [123] and U937 cells [72] as surrogates to LSE and Kupffer cells.”
MethodInfluential
Cited by
Applications of tumor chip technology
Hachey, S. J., & Hughes, C. C. W. (2018) · Lab on a Chip · doi:10.1039/c8lc00330k · Cited by 128
Organs-on-chip monitoring: sensors and other strategies
Kilic, T., Navaee, F., Stradolini, F., Renaud, P., & Carrara, S. (2018) · Microphysiological Systems · doi:10.21037/mps.2018.01.01 · Cited by 96
“Thanks to recent advancements in microfabrication techniques as well as 3D bioprinting (23,24), various liveron-a-chip platforms have been developed so far (25-29).”
BackgroundWang, Y., Wu, D., Wu, G., Wu, J., Lu, S., Lo, J., He, Y., Zhao, C., Zhao, X., Zhang, H., et al. (2020) · Theranostics · doi:10.7150/thno.38736 · Cited by 93
“Although chemotherapy plays a key part in the plethora of options for the clinical management of metastatic cancer, the success rate of developing effective chemo-compounds is less than 5% due to the limitation of conventional models [5].”
BackgroundYou-on-a-chip’ for precision medicine
Low, L. A., & Tagle, D. A. (2018) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2018.1456333 · Cited by 18
Microphysiological systems as models for immunologically ‘cold’ tumors
Gaebler, D., Hachey, S. J., & Hughes, C. C. W. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1389012 · Cited by 14
Metadata
- Authors
- Khazali, A. S., Clark, A. M., & Wells, A.
- Venue
- Stem Cell Reviews and Reports
- Published
- 2017-04-19
- Volume
- 13
- Issue
- 3
- Pages
- 364-380
- ISSN
- 1550-8943 (ISSN-L)
- 1558-6804
- OpenAlex
- W2605676872
- Cited by
- 32
- References
- 22
- FWCI
- 1.98
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Pathway to Personalizing Therapy for Metastases Using Liver-on-a-Chip Platforms. https://app.cochat.ai/papers/10.1007/s12015-017-9735-3
- The paper
- Khazali, A. S., Clark, A. M., & Wells, A. (2017). A Pathway to Personalizing Therapy for Metastases Using Liver-on-a-Chip Platforms. Stem Cell Reviews and Reports. https://doi.org/10.1007/s12015-017-9735-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.